[Controlled pilot study with combination chemotherapy in testicular carcinomas (author's transl)].
In 24 previously untreated patients with advanced testicular carcinoma, the combination of adriamycin, vincristine and methotrexate (AVM) was tested in a prospective randomized study against a combination of non-cross resistant drugs including vinblastine, bleomycin and mithramycin (VBM). Complete and partial (greater than 50%) remission was observed in 4 out of 13 patients treated with AVM and in 3 out of 11 given VBM. In one patient receiving AVM and in two patients treated with VBM, the response at the level of previous inoperable retroperitoneal metastatic lymph nodes allowed a subsequent radical lymph node dissection. After cross-over a partial response for 6 months was obtained in only one patient treated with VBM while none was observed in 4 patients receiving AVM. Both combinations were well tolerated. However, their therapeutic activity seems to be definitely lower with respect to treatment with vinblastine followed by continuous infusion with bleomycin.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D013736:Testicular Neoplasms / Q000188:drug therapy*; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014750:Vincristine; D004317:Doxorubicin; D008727:Methotrexate
Studio pilota con  due associazioni chemioterapiche nei carcinomi testicolari